OPTIMµM
Live / Registered — Registered and renewed (as of 26 Jun 2025)
What this means for you
Registered since 01 Sept 2015. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 01 Sept 2025).
Record
- Serial number
- 86383746
- Registration number
- 4802411
- Mark type
- Stylized text
- Filed
- 03 Sept 2014
- Published for opposition
- 16 Jun 2015
- Registered
- 01 Sept 2015
- Next maintenance due
- 01 Sept 2025
- Attorney of record
- C. Blair Barbieri
Goods and services
- Class 040 — Treatment of materials: Manufacturing services for others in the area of pharmaceutical drug delivery systems, including continuous release, pulsatile release, extended release, sustained release, taste masked release, and delayed release systems, clinical manufacturing of drug formulations for others to support clinical trials, fabrication and preparation of active pharmaceutical ingredients for others, technology scale-up services for others, and integration of technology into manufacturing processes for others, all relating to multiple drug product formats, namely, semi-solids, solutions, suspensions, particulates, solid dispersions, solid solutions and injectables, all for oral delivery
- Class 042 — Scientific and technological services: Pharmaceutical drug delivery technology development services; pharmaceutical drug delivery technology development services, namely, research and development in the area of pharmaceutical drug delivery systems, including continuous release, pulsatile release, extended release, sustained release, taste masked release, and delayed release systems, consisting of selection of drug formulation and delivery systems to optimize performance of active pharmaceutical ingredients, analytic techniques to test drug formulations, analytic services to detect, identify and quantify drug components, stability testing, physical characterization of drug formulations, in-vitro release testing, all relating to multiple drug product formats, namely, semi-solids, solutions, suspensions, particulates, solid dispersions, solid solutions and injectables, all for oral delivery
Owner
- Adare Pharmaceuticals USA, Inc., Philadelphia, PA, US
- Orbis Biosciences, Inc., Kansas City, KS, US
- Orbis Biosciences, Inc., Kansas City, KS, US
- Orbis Biosciences, Inc., Kansas City, KS, US
Prosecution history
- 26 Jun 2025 — NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
- 26 Jun 2025 — REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
- 26 Jun 2025 — REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
- 26 Jun 2025 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 14 Feb 2025 — TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
- 14 Feb 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 14 Feb 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 14 Feb 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 14 Feb 2025 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 14 Feb 2025 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 17 Jan 2025 — TEAS SECTION 8 & 9 RECEIVED
- 01 Sept 2024 — COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
- 08 Jul 2021 — NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
- 08 Jul 2021 — REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
- 08 Jul 2021 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL